Trusted Resources: Education
Scientific literature and patient education texts
Novel Approaches for the Management of AL Amyloidosis
source: Current Hematologic Malignancy Reports
year: 2018
authors: Joseph NS, Kaufman JL
summary/abstract:Purpose of Review:
Light-chain-associated (AL) amyloidosis is a rare disease with a poor prognosis. However, we have made recent strides in more accurate diagnosis and effective treatment. Here, we discuss the most recent updates and advancements during the past year in the diagnosis, prognostication, and management of AL amyloidosis both in the upfront and relapsed setting.
Recent Findings:
New imaging modalities, such as cardiac magnetic resonance (CMR) and use of fluorine-labeled radiotracers, are emerging as an important diagnostic tool in conjunction with biomarkers in the diagnosis, prognosis, and monitoring of the effects of therapy. In addition, ongoing evaluation of plasma cell-directed therapeutics, including daratumumab, pomalidomide, and ixazomib, as well as promising targeted novel therapies, such as the monoclonal antibody NEOD001, are in development. In conclusion, incorporating the use of plasma cell-directed therapy and novel agents targeting the amyloid deposits itself hold enormous potential in achieving improved outcomes in AL amyloidosis.
organization: Emory University, USADOI: 10.1007/s11899-018-0450-1
read more full text
Related Content
-
Webinar Presentation by Morie Gertz on AL Amyloidosis Overviewhttps://www.youtube.com/watch?v=qscVgShp...
-
Newer Therapies for Amyloid CardiomyopathyThe heart and the kidneys are the most c...
-
Emerging Therapeutic Targets Currently Under Investigation for the Treatment of Systemic AmyloidosisSystemic amyloidosis occurs when one of ...
-
MAGE Genes: Prognostic Indicators in AL Amyloidosis PatientsA high frequency of MAGE-CT (cancer te...
-
Diet Guidelines for Immunosuppressed PatientsFood safety is important during and afte...
-
Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detectionOxford, UK, April 26th, 2023 — Ultrom...
-
Tegsedi™ to be Available on the NHS for hATTR AmyloidosisAkcea Therapeutics UK Ltd., has announce...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.